Autres langues PYC Therapeutics Limited

Actions

PYC

AU000000PYC7

Recherche biotechnologique et médicale

Temps Différé Australian S.E. 05:55:58 14/09/2026			Varia. 5j.	Varia. 1 janv.
2,260 ^AUD	-1,74%		-9,96%	+36,56%

11/09	PYC Therapeutics annonce l'administration de la première dose au premier patient de l'extension en ouvert de l'étude sur son candidat-médicament contre la polykystose rénale	MT
04/09	Transcript : PYC Therapeutics Limited - Special Call

Autres langues

11/09	PYC Therapeutics Says First Patient Dosed in Open-Label Extension of Drug Candidate Study in Polycystic Kidney Disease
03/09	ASX Biggest Gainers
30/08	PYC Therapeutics Fiscal 2026 Loss Narrows, Revenue Up
28/08	PYC Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2026
07/08	ASX Biggest Losers
04/08	ASX Biggest Gainers
29/07	PYC Therapeutics Secures Approval for Higher Dosage in Phase 1b Multiple Ascending Dose Study in Polycystic Kidney Disease
21/07	Australian Shares Flat; NEXTDC Reports 11% Increase in Pro Forma Contracted Utilization
21/07	PYC Therapeutics Says ADOA Patients Show Sustained Visual Acuity, Retinal Stress Improvements in Drug Candidate Trials; Shares Down 4%
21/07	PYC Therapeutics Says ADOA Patients Show Sustained Visual Acuity, Retinal Stress Improvements in Drug Candidate Trials
08/07	PYC Therapeutics Says US Patent Office Grants Composition of Matter Patents for Three Drug Candidates
07/07	PYC Therapeutics Names CFO
07/07	Pyc Therapeutics Limited Announces Appointment of Thomas Ulmer as Chief Financial Officer
15/06	PYC Therapeutics Announces Company Secretary Changes, Effective June 15, 2026
07/05	PYC Therapeutics Starts Phase 1b Multiple Ascending Dose Study in Polycystic Kidney Disease; Shares Up Nearly 5%
27/04	PYC Therapeutics' Blinding Eye Disease Treatment Candidate Gets Orphan Drug Designation in Europe
15/04	PYC Therapeutics Advances Optic Atrophy Drug to Multiple-Dose Study After Safety Clearance; Shares Up 7%
17/03	Bell Potter rates PYC as Speculative Buy
16/03	PYC Therapeutics Agrees on Framework for Registrational Study Design for Blinding Eye Disease Drug Candidate New Drug Application
04/03	PYC Therapeutics Limited Limited Announces Joint Company Secretary Changes
04/03	PYC Therapeutics Completes Retail Entitlement Offer, Raises AU$47 Million
27/02	PYC Therapeutics Advances Polycystic Kidney Disease Drug Candidate to Next Dose Cohort
24/02	PYC Therapeutics Shares Flat As It Posts Narrower Fiscal H1 Loss, Lower Revenue
23/02	PYC Therapeutics posts HY revenues from ordinary activities A$11.0 million
23/02	PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2025